Neurotoxicity of Commonly Used Antineoplastic Agents
NEJM 291:75, 1271974., Weiss,H.,et al, 1974
An Open-Label Trial of Combination Therapy With Interferon B-1a and Oral Methotrexate in MS
Neurol 58:314-317, Calabresi,P.A.,et al, 2002
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Low-Dose Oral Methotrexate in Chronic Progressive Multiple Sclerosis:Analyses of Serial MRIs
Neurol 47:1153-1157, Goodkin,D.E.,et al, 1996
Low-Dose (7. 5mg) Oral Methotrexate Reduces the Rate of Progression in Chronic Progressive Multiple Sclerosis
Ann Nuerol 37:30-40, 51995., Goodkin,D.E.,et al, 1995
Intraventricular Methotrexate Therapy of Leptomeningeal Metastasis from Breast Carcinoma
Neurol 33:1565-1572, OngerboerdeVisser,B.W.,et al, 1983
Meningeal Carcinomatosis
Arch Neurol 38:696-699, Theodore,W.H.,et al, 1981
Polymyositis & Dermatomyositis
NEJM 292:344, 1975, 292:403975., Bohan,A.,et al, 1975